peso 888 Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says

The Food and Drug Administration on Wednesday declared an end to the two-year shortage of tirzepatidepeso 888, the substance in the popular weight-loss medication Zepbound and the diabetes drug Mounjaro. The end of the shortage means that far more people could soon be able to access the brand-name drugs.

It is also certain to disrupt the big business of copycat weight-loss drugs, compounded medications that have been cheaper and more available — and are only allowed to be manufactured when brand-name drugs are in short supply.

Many people have not been able to get their hands on the brand-name medications since 2022, shortly after Mounjaro was first introduced in the United States. Demand for the drug was so great that it quickly went into short supply. That drove patients to seek out alternatives from compounding pharmacies, which, during shortages, can create their own versions of medications that do not have to be approved by the F.D.A. By some estimates, millions of Americans have taken compounded weight-loss and diabetes drugs.

Now that the shortage is resolved, pharmacies must immediately stop preparing compounded copies of Mounjaro and Zepbound, said Scott Brunner, the chief executive of the Alliance for Pharmacy Compounding.

“There are many, many, many more patients than normal who are relying on compounded copies of F.D.A.-approved drugs,” he said. “It’s those folks that are going to have to scramble.”

Compounding pharmacies have historically tailor-made drugs for patients with specific needs, like reformulating a pain reliever if someone is allergic to one of its ingredients. But they have taken on a far more prominent role as demand has soared for diabetes and weight-loss drugs. The interest in these compounded drugs has largely been fueled by upstart telehealth companies like Ro and Hims, which advertise access to them for hundreds of dollars less than the name-brand medications.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.

Thank you for your patience while we verify access.

Already a subscriber? Log in.

Want all of The Times? Subscribe.peso 888

• are
• and
• peso 888
• Mounjaro
• Zepbound